Literature DB >> 31411557

Pharmacogenomic considerations for medications in the perioperative setting.

Ellie H Jhun1,2, Jeffrey L Apfelbaum3, David M Dickerson3,4, Sajid Shahul3, Randall Knoebel5, Keith Danahey6,7, Mark J Ratain1,6,8, Peter H O'Donnell1,6,8.   

Abstract

Several high-profile examples of adverse outcomes from medications used in the perioperative setting are well known (e.g., malignant hyperthermia, prolonged apnea, respiratory depression, inadequate analgesia), leading to an increased understanding of genetic susceptibilities underlying these risks. Pharmacogenomic information is increasingly being utilized in certain areas of medicine. Despite this, routine preoperative genetic screening to inform medication risk is not yet standard practice. In this review, we assess the current readiness of pharmacogenomic information for clinical consideration for several common perioperative medications, including description of key pharmacogenes, pharmacokinetic implications and potential clinical outcomes. The goal is to highlight medications for which emerging or considerable pharmacogenomic information exists and identify areas for future potential research.

Entities:  

Keywords:  analgesia; anesthesia; genetic markers; genomics; genotyping; perioperative; pharmacogenetics; pharmacogenomic; precision medicine; surgery

Mesh:

Year:  2019        PMID: 31411557      PMCID: PMC6949515          DOI: 10.2217/pgs-2019-0040

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.638


  88 in total

1.  CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.

Authors:  K Adachi; T Katsube; A Kawamura; T Takashima; M Yuki; K Amano; S Ishihara; R Fukuda; M Watanabe; Y Kinoshita
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

2.  Prolonged apnea after administration of succinylcholine.

Authors:  H M RUBINSTEIN; M K ROSENBERG; J H BOLGLA; B M COHEN
Journal:  N Engl J Med       Date:  1960-06-02       Impact factor: 91.245

3.  Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.

Authors:  Parvaz Madadi; Ursula Amstutz; Michael Rieder; Shinya Ito; Vincent Fung; Soomi Hwang; Jacques Turgeon; Veronique Michaud; Gideon Koren; Bruce C Carleton
Journal:  J Popul Ther Clin Pharmacol       Date:  2013-11-06

4.  Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters.

Authors: 
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 5.  Treatment of acute postoperative pain.

Authors:  Christopher L Wu; Srinivasa N Raja
Journal:  Lancet       Date:  2011-06-25       Impact factor: 79.321

Review 6.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.

Authors:  Stephen G Gonsalves; Robert T Dirksen; Katrin Sangkuhl; Rebecca Pulk; Maria Alvarellos; Teresa Vo; Keiko Hikino; Dan Roden; Teri E Klein; S Mark Poler; Sephalie Patel; Kelly E Caudle; Ronald Gordon; Barbara Brandom; Leslie G Biesecker
Journal:  Clin Pharmacol Ther       Date:  2019-01-24       Impact factor: 6.875

7.  Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.

Authors:  Shuen-Iu Hung; Wen-Hung Chung; Zhi-Sheng Liu; Chien-Hsiun Chen; Mo-Song Hsih; Rosaline Chung-yee Hui; Chia-Yu Chu; Yuan-Tsong Chen
Journal:  Pharmacogenomics       Date:  2010-03       Impact factor: 2.533

8.  Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.

Authors:  Rasmus Steen Pedersen; Per Damkier; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2006-06-09       Impact factor: 2.953

9.  Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.

Authors:  Thomas Rau; Roland Heide; Klaus Bergmann; Henrike Wuttke; Ulrike Werner; Nico Feifel; Thomas Eschenhagen
Journal:  Pharmacogenetics       Date:  2002-08

10.  Ensembl 2016.

Authors:  Andrew Yates; Wasiu Akanni; M Ridwan Amode; Daniel Barrell; Konstantinos Billis; Denise Carvalho-Silva; Carla Cummins; Peter Clapham; Stephen Fitzgerald; Laurent Gil; Carlos García Girón; Leo Gordon; Thibaut Hourlier; Sarah E Hunt; Sophie H Janacek; Nathan Johnson; Thomas Juettemann; Stephen Keenan; Ilias Lavidas; Fergal J Martin; Thomas Maurel; William McLaren; Daniel N Murphy; Rishi Nag; Michael Nuhn; Anne Parker; Mateus Patricio; Miguel Pignatelli; Matthew Rahtz; Harpreet Singh Riat; Daniel Sheppard; Kieron Taylor; Anja Thormann; Alessandro Vullo; Steven P Wilder; Amonida Zadissa; Ewan Birney; Jennifer Harrow; Matthieu Muffato; Emily Perry; Magali Ruffier; Giulietta Spudich; Stephen J Trevanion; Fiona Cunningham; Bronwen L Aken; Daniel R Zerbino; Paul Flicek
Journal:  Nucleic Acids Res       Date:  2015-12-19       Impact factor: 16.971

View more
  3 in total

1.  Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade in Response to Succinylcholine.

Authors:  Guang-Dan Zhu; Eric Dawson; Angela Huskey; Ronald J Gordon; Andria L Del Tredici
Journal:  Pharmgenomics Pers Med       Date:  2020-09-30

Review 2.  Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics.

Authors:  Ivana Budic; Tatjana Jevtovic Stoimenov; Dimitrije Pavlovic; Vesna Marjanovic; Ivona Djordjevic; Marija Stevic; Dusica Simic
Journal:  Front Med (Lausanne)       Date:  2022-02-28

3.  A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.

Authors:  Julie A Johnson; Larisa H Cavallari; Cameron D Thomas; Hari K Parvataneni; Chancellor F Gray; Justin T Deen; Hernan A Prieto; Luis F Pulido; Amanda R Elsey; Erica N Elwood; Petr Starostik; Yan Gong; Roger B Fillingim
Journal:  Genet Med       Date:  2021-01-08       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.